[Pathogenetic role of HBV in liver cell carcinoma of Western European patients].
Tumour (n = 338) and corresponding liver tissue (n = 276) of liver cell carcinoma (LCC) patients including 31 Asiatic cases was studied with immunohistochemical methods (IHC) for the expression of HBs (7MABs and 2 PABs), HBc, HBe, HBx, and preS antigens. HBV-DNA was detected with in situ hybridisation (ISH) employing digoxigenin-labeled DNA probes. Furthermore, polymerase chain reaction (PCR) was done for a part of the X-ORF (1542+, 1746-). Tumours from the European patients were fibrolamellar (FLC; n = 8), hepatocellular (HCC; n = 260), mixed hepatocellular/cholangiocellular (HCC/CCC; n = 23), and pure cholangiocellular carcinomas (CCC; n = 16). Of the Asiatic cases, 56.5% contained HBs in liver and 64.5% in tumour tissue, of the European cases these were 21.7% and 29.6%, respectively. HBc, HBe, and preS antigens were found only in few cases. HBV positive rates with ISH were 82.6% and 87.1% for Asiatic, and 45.3% and 51.7% for European cases, respectively. Altogether, 93.6% of the Asiatic and 64.2% of the European patients were positive for HBV with IHC or ISH. HCC/CCC and CCC showed slightly lower HBV positive rates than HCC. Over 90% of the cases had HBx in liver and tumour tissue. PCR revealed HBV positive rates of 73.2% for liver and 90.1% for tumour tissue irrespective of patients descent and tumour type. Thus, HBV seems to represent a pathogenetic factor for LCC in Western European patients irrespective of the tumour type. The existence of the "mixed tumours" HCC/CCC as well as the frequent HBV-positivity of tumours with cholangiocellular differentiation document that CCC belong to the category LCC.